Lunai Bioworks Inc.
LNAI evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for LNAI—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · LNAI
Lunai Bioworks Inc. is a pre-clinical biotechnology company focused on AI-driven neurology and oncology diagnostics and therapeutic development, with no revenue and a going concern uncertainty.
Key risk: Going concern uncertainty
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Financial data as of Mar 31, 2026.
Lunai Bioworks Inc. is a pre-clinical biotechnology company focused on AI-driven neurology and oncology diagnostics and therapeutic development, with no revenue and a going concern uncertainty.
- Lunai Bioworks is a pre-clinical biotechnology company with no revenue to date [sec_mda · as of 2025-09-29].
- As of March 31, 2026, the company had cash and cash equivalents of $3,155,272 and an accumulated deficit of $512 million [sec_mda · as of 2026-05-15].
- The company has filed provisional patent applications for intranasal delivery of CNS agents and combination therapeutics for CNS disorders [sec · filed 2026-05-01].
- Management has streamlined the organization to focus on AI-driven diagnostics and therapeutic development, but additional funding is required to continue operations [sec_mda · as of 2026-02-17].
- The company changed its name from Renovaro Inc. to Lunai Bioworks Inc. in August 2025 [sec_mda · as of 2026-05-15].
What works
- The company has filed multiple patent applications covering CNS-active drug formulations and combination therapeutics, indicating ongoing intellectual property development [sec · filed 2026-05-01].
- Management has reduced overhead and streamlined the organization to focus on its core AI-driven platform, which may improve operational efficiency [sec_mda · as of 2026-02-17].
What to weigh
- The company has incurred substantial recurring losses, has an accumulated deficit of $512 million, and its cash position of $3.2 million as of March 31, 2026, is insufficient to sustain operations without additional funding [sec_mda · as of 2026-05-15].
- Lunai Bioworks has no revenue and all product candidates are in discovery or pre-clinical stages, with no assurance of successful development or market approval [sec_mda · as of 2025-09-29].
- The company faces a going concern uncertainty and may need to seek bankruptcy protection if additional funding is not obtained [sec_mda · as of 2026-05-15].
- There is no guarantee that additional equity or debt financing will be available on acceptable terms, and any equity financing could cause significant dilution to existing stockholders [sec_mda · as of 2026-05-15].
From the filings
Quoted directly from source documents.
The company has an accumulated deficit of $512 million as of March 31, 2026.
“As of March 31, 2026, the Company had cash and cash equivalents of $3,155,272, an accumulated deficit of $512,0”
SEC MD&A · May 15, 2026
The company has no revenue and is pre-clinical.
“Lunai Bioworks is an early-stage biotechnology company and has not generated any revenues to date. All of our product candidates are in the discovery stage or pre-clinical development stage.”
SEC MD&A · September 29, 2025
The company changed its name from Renovaro Inc. to Lunai Bioworks Inc. in August 2025.
“On August 20, 2025, the Company changed its corporate name from Renovaro Inc. to Lunai Bioworks Inc.”
SEC MD&A · May 15, 2026
The company has filed provisional patent applications for CNS drug delivery and combination therapeutics.
“U.S. Provisional Patent Application No. 64/042,938, filed on April 17, 2026, titled "Drug Delivery of CNS Agents," which generally covers multi-agent intranasal-delivery formulations including combinations of CNS-active pharmaceutical agents”
SEC filings · May 1, 2026
Risks & what to watch (4)›
Key risks
- Going concern uncertainty — The company has substantial losses and may need to suspend or cease operations if additional funding is not obtained [sec_mda · as of 2026-05-15].
- No revenue or approved products — All product candidates are pre-clinical; no assurance of successful development or market approval [sec_mda · as of 2025-09-29].
- Dependence on external financing — Additional funding may not be available on acceptable terms; equity financing could cause significant dilution [sec_mda · as of 2026-05-15].
- Limited operating history — Very limited relevant operating history; no guarantee of future profitability [sec_mda · as of 2025-09-29].
What to watch
- Ability to secure additional debt or equity financing to continue operations [sec_mda · as of 2026-05-15].
- Progress of pre-clinical development and any advancement toward clinical trials [sec_mda · as of 2025-09-29].
- Outcome of patent applications and potential partnerships or licensing deals [sec · filed 2026-05-01].
- Any changes in cash runway or going concern status in future filings [sec_mda · as of 2026-05-15].
Sources: SEC filings · SEC MD&A · Generated August 10, 2026 · How we verify sources →
Run Lunai Bioworks Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Lunai Bioworks Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
9.7 months
OCF -$1M · Net income -$3M
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
27
Total value held
$372K
| Holder | Shares | Value |
|---|---|---|
| geode capital management, llc | 182,237 | $74K |
| blackrock, inc. | 127,314 | $52K |
| nine masts capital ltd | 102,426 | $42K |
| citigroup inc | 100,095 | $41K |
| vanguard capital management llc | 96,499 | $39K |
| vanguard fiduciary trust co | 69,136 | $28K |
| xtx topco ltd | 52,484 | $21K |
| northern trust corp | 37,402 | $15K |
| state street corp | 35,728 | $15K |
| two sigma securities, llc | 25,095 | $10K |
Showing top 10 of 27 institutional holders of Lunai Bioworks Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 28, 2026- % of float
- 2.5%
- Days to cover
- 0.0
- Shares short
- 779,601
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
LNAI short interestGovernance
Frequently asked questions
What is the AI investment thesis for Lunai Bioworks Inc.?
Lunai Bioworks Inc. is a pre-clinical biotechnology company focused on AI-driven neurology and oncology diagnostics and therapeutic development, with no revenue and a going concern uncertainty.
Who is the CEO of Lunai Bioworks Inc.?
Mr. David H. Weinstein is the chief executive officer of Lunai Bioworks Inc. (LNAI).
Where is Lunai Bioworks Inc. headquartered?
Lunai Bioworks Inc. (LNAI) is headquartered in Los Angeles, CA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.